Faricimab

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 490 publications

Association of Molar Dose and Early Retinochoroidal Blood Flow Changes After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy.

Association of Molar Dose and Early Retinochoroidal Blood Flow Changes After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy.

Journal: Investigative ophthalmology & visual science

Published: January 14, 2026

Recurrent sterile endophthalmitis following intravitreal Faricimab: A case report.

Recurrent sterile endophthalmitis following intravitreal Faricimab: A case report.

Journal: Retinal cases & brief reports

Published: January 06, 2026

Alpha-Gal Syndrome Allergy to Intravitreal Administration of Anti-Vascular Endothelial Growth Factor Agents.

Alpha-Gal Syndrome Allergy to Intravitreal Administration of Anti-Vascular Endothelial Growth Factor Agents.

Journal: Journal of vitreoretinal diseases

Published: January 02, 2026

Pilot Study of Choroidal Synphlebia.

Pilot Study of Choroidal Synphlebia.

Journal: Retina (Philadelphia, Pa.)

Published: December 30, 2025

Letter to the Editor: Comment on Palmieri et al.'s "Uveitis Following Intravitreal Injections of Faricimab: A Case Report".

Letter to the Editor: Comment on Palmieri et al.'s "Uveitis Following Intravitreal Injections of Faricimab: A Case Report".

Journal: Ocular immunology and inflammation

Published: December 29, 2025

Intravitreal faricimab treatment for traumatic choroidal rupture and macular neovascularization in angioid streaks: A case report.

Intravitreal faricimab treatment for traumatic choroidal rupture and macular neovascularization in angioid streaks: A case report.

Journal: European journal of ophthalmology

Published: December 24, 2025

Use of faricimab in neovascular age-related macular degeneration and diabetic macular edema in Russia. Results of the FARWATER retrospective study

Use of faricimab in neovascular age-related macular degeneration and diabetic macular edema in Russia. Results of the FARWATER retrospective study

Journal: Vestnik oftalmologii

Published: December 23, 2025

Pigment epithelial detachment as a biomarker for faricimab treatment outcomes in naïve neovascular age-related macular degeneration.

Pigment epithelial detachment as a biomarker for faricimab treatment outcomes in naïve neovascular age-related macular degeneration.

Journal: European journal of ophthalmology

Published: December 17, 2025

Intraocular inflammation incidence and real-world safety of intravitreal faricimab treatment across retinal indications.

Intraocular inflammation incidence and real-world safety of intravitreal faricimab treatment across retinal indications.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: December 02, 2025

Massive Submacular Hemorrhage Following Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration.

Massive Submacular Hemorrhage Following Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration.

Journal: Cureus

Published: November 27, 2025

Full-Thickness Macular Hole After Faricimab Treatment for Branch Retinal Vein Occlusion-Associated Macular Edema with Vitreomacular Traction: A Case Report.

Full-Thickness Macular Hole After Faricimab Treatment for Branch Retinal Vein Occlusion-Associated Macular Edema with Vitreomacular Traction: A Case Report.

Journal: The American journal of case reports

Published: November 25, 2025

Early anatomical outcomes of faricimab vs. aflibercept 2 mg in treatment-naïve neovascular AMD and PCV: A head-to-head comparative study in Taiwan.

Early anatomical outcomes of faricimab vs. aflibercept 2 mg in treatment-naïve neovascular AMD and PCV: A head-to-head comparative study in Taiwan.

Journal: Journal of the Chinese Medical Association : JCMA

Published: November 24, 2025

Showing 1-12 of 490

Last Updated: 02/24/2026